NCT05311488Completed
Early Detection of Neuropathy in ATTRv
Early Detection of Peripheral Neuropathy in Hereditary Transthyretin Amyloidosis
Source: ClinicalTrials.gov · Last updated 12 Mar 2026
Brief summary (registry, in English)
The purpose of the study is to evaluate and compare different tools that are used to detect evidence of peripheral neuropathy in patients with TTRv.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 47 (actual)
- First submitted
- 16 Mar 2022
- Start date
- Feb 2022
- Primary completion date
- Nov 2025
- Lead sponsor
- University of Pennsylvania
- Diseases
- Amyloidosis
- NCT number
- NCT05311488
What you commit to
- Study type: Observational
- Participants enrolled: 47
- From Feb 2022 to the primary completion date, Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with risk factors for neuropathy (diabetes, history of neuropathy in the family, neurotoxic drugs) or with neurological disorder associated with elevated NFL
Other
- Patients with neuropathy other than TTR amyloid
Who the study is looking for
- Patients with known TTR mutations and neuropathy
- Patients with TTR mutation and no symptoms within less than 10 years of typical onset of disease
- Age criteria must meet the following:
- Non V122I mutations, Age 40 or older.
- V122 I mutations, 55 or older.
- Healthy persons without neuropathy
- The following distribution of age ranges will be considered when enrolling healthy participants:
- 5 patients age 30-40
- 5 patients age 40-50
- 5 patients age 50-60
- 5 patients age 60-70
- Healthy control subjects for this study are defined as subjects with no symptoms of neuropathy or risk factors for neuropathy such as family history of hereditary neuropathy, chemotherapy, diabetes, autoimmune disease, or vitamin deficiency. Their status will be verified by medical records review.
Age in the registry: 30 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.